



Freedom of Information Team  
De La Court House  
Queen Alexandra Hospital  
Southwick Hill Road  
Portsmouth  
Hampshire  
PO6 3LY

Name:  
Email:  
Date: 24/07/2023  
Ref: 23-24 238

Dear

**RE: Freedom of Information request**

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 12/07/2023. Please see responses to your requests below.

**I am researching the incidence and treatment of Urothelial and Colorectal Cancer. I would greatly appreciate if you could answer the following three questions.**

**1. In the past 3 months, how many patients have been treated for urothelial cancer with the following agents?**

Please see table below, the 3-month period used is Dec 2022 - Feb 2023, as February 2023 is our latest complete SACT dataset.

Regimen	Count
Avelumab	5
Atezolizumab	6
Carboplatin with Gemcitabine	5
Carboplatin single or in any other combination	<5
Cisplatin with Gemcitabine	<5
Cisplatin single or in any other combination	0
Nivolumab	0
Pembrolizumab	0
Any other systemic anti-cancer therapy	<5
Palliative care only	0

The Trust is unable to provide precise figures when these are five or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

**2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?**

Portsmouth Hospitals University NHS Trust is not participating in any trails for the treatment of urothelial cancer.

**3. In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents?**

Please see table below, the 3-month period used is Dec 2022 - Feb 2023, as February 2023 is our latest complete SACT dataset.

Regimen	Count
Aflibercept	0
Bevacizumab	<5
Capecitabine	12
CAPIRI	0
CAPOX (XELOX)	27
Cetuximab in combination with FOLFIRI/FOLFOX	0
Cetuximab not in combination with FOLFIRI or FOLFOX	<5
Irinotecan only	0
FOLFIRI	33
FOLFOX	13
Fluorouracil (5FU) only	<5
Oxaliplatin only	0
Nivolumab	0
Panitumumab in combination with FOLFIRI/FOLFOX	23
Panitumumab not in combination with FOLFIRI or FOLFOX	<5
Pembrolizumab	0
Raltitrexed	<5
Ramucirumab	0
Regorafenib	0
Tegafur + Uracil	<5
Any other systemic anti-cancer therapy	59
Palliative care only	0

Please see exemption in Question 1.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on [Information.Governance@porthosp.nhs.uk](mailto:Information.Governance@porthosp.nhs.uk) or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team

**Working together** To drive excellence in care for our patients and communities